161 results
Page 5 of 9
8-K
EX-99.3
lnz yar1jeixmwawxll9
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
nkg31ftlkd jkp27
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
wybem1z0lj mmv
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
8-K
EX-99.1
mucj9sn8q em5abc
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am
8-K
EX-99.1
bbmy d5cxstzr9xkp4
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
8c67rb5
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
ys9fkcmvlfq0y0
4 Sep 19
Other Events
5:05pm
8-K
EX-99.1
v5i6cmp ou4q
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am
8-K
EX-99.1
0i1fszc5 r2j16w6enaf
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
c5pv vsjmjf9mwk1bc
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
8-K
EX-99.1
xa7np0n85hnyih8g
2 May 19
Other Events
3:24pm
8-K
EX-99.1
znq1854
2 May 19
Agios Reports Business Highlights and First Quarter 2019 Financial Results
7:24am
8-K
EX-99.1
rjiqqidwbdd yjp7ajm2
14 Feb 19
Agios Reports Fourth Quarter and Full Year 2018 Financial Results
7:16am
8-K
EX-99.1
vcqis74aidpt76sle2
7 Jan 19
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value
7:48am
8-K
EX-99.1
x0jinhx0zb8mh
3 Dec 18
Other Events
4:03pm